PubRank

American journal of nuclear medicine and molecular imaging (Am J Nucl Med Mol Imaging)

Journal PubWeight™ 178.09‹?›

Top papers

Rank Title Year PubWeight™‹?›
51 Multispectral visualization of surgical safety-margins using fluorescent marker seeds. 2012 0.85
52 Dosimetry of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 in rodents, pigs, non-human primates and human - repeated scanning in human is possible. 2015 0.85
53 Development of NGR peptide-based agents for tumor imaging. 2011 0.85
54 Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. 2013 0.85
55 Dual tracer imaging of SPECT and PET probes in living mice using a sequential protocol. 2012 0.85
56 (18)F-misonidazole PET imaging of hypoxia in micrometastases and macroscopic xenografts of human non-small cell lung cancer: a correlation with autoradiography and histological findings. 2013 0.84
57 Re-evaluating the potentials and limitations of (99m)Tc-aprotinin scintigraphy for amyloid imaging. 2013 0.84
58 The role of molecular imaging in diagnosis of deep vein thrombosis. 2014 0.84
59 Molecular imaging for early prediction of response to Sorafenib treatment in sarcoma. 2013 0.84
60 Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer. 2012 0.84
61 Influence of CT-based attenuation correction on dopamine transporter SPECT with [(123)I]FP-CIT. 2015 0.84
62 Pictorial review of SPECT/CT imaging applications in clinical nuclear medicine. 2012 0.84
63 Quantitative carotid PET/MR imaging: clinical evaluation of MR-Attenuation correction versus CT-Attenuation correction in (18)F-FDG PET/MR emission data and comparison to PET/CT. 2015 0.83
64 Molecular imaging of insulin-like growth factor 1 receptor in cancer. 2012 0.83
65 Dosimetry of [(177)Lu]-DO3A-VS-Cys(40)-Exendin-4 - impact on the feasibility of insulinoma internal radiotherapy. 2015 0.83
66 Recent advances in diagnosis and treatment of gliomas using chlorotoxin-based bioconjugates. 2014 0.83
67 Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies. 2015 0.83
68 Quantitative and qualitative comparison of continuous bed motion and traditional step and shoot PET/CT. 2014 0.83
69 Kinetic modeling in PET imaging of hypoxia. 2014 0.83
70 [(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer. 2016 0.83
71 The use of dynamic nuclear polarization (13)C-pyruvate MRS in cancer. 2015 0.82
72 Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients. 2015 0.82
73 Stem cell tracking with optically active nanoparticles. 2013 0.82
74 (68)Ga-labeled superparamagnetic iron oxide nanoparticles (SPIONs) for multi-modality PET/MR/Cherenkov luminescence imaging of sentinel lymph nodes. 2013 0.82
75 PET brain kinetics studies of (11)C-ITMM and (11)C-ITDM,radioprobes for metabotropic glutamate receptor type 1, in a nonhuman primate. 2014 0.82
76 Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma. 2013 0.82
77 PET/MR imaging of atherosclerosis: initial experience and outlook. 2013 0.82
78 In vivo validation and 3D visualization of broadband ultrasound molecular imaging. 2013 0.82
79 Molecular MRI of VEGFR-2 reveals intra-tumor and inter-tumor heterogeneity. 2013 0.82
80 Peptide targeted high-resolution molecular imaging of prostate cancer with MRI. 2014 0.82
81 Bilateral peripheral neural activity observed in vivo following unilateral nerve injury. 2013 0.82
82 EATRIS, a European initiative to boost translational biomedical research. 2013 0.82
83 Combined SPECT and Multidetector CT for Prostate Cancer Evaluations. 2012 0.81
84 Molecular MRI differentiation of VEGF receptor-2 levels in C6 and RG2 glioma models. 2013 0.81
85 In vivo molecular imaging of cancer stem cells. 2014 0.81
86 Biodistribution and pharmacokinetics of recombinant α1-microglobulin and its potential use in radioprotection of kidneys. 2015 0.80
87 Organ biodistribution of Germanium-68 in rat in the presence and absence of [(68)Ga]Ga-DOTA-TOC for the extrapolation to the human organ and whole-body radiation dosimetry. 2013 0.80
88 Comparison of FDG-PET/CT images between chronic renal failure patients on hemodialysis and controls. 2015 0.80
89 Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study. 2015 0.80
90 Assessment of vulnerable atherosclerotic and fibrotic plaques in coronary arteries using (68)Ga-DOTATATE PET/CT. 2014 0.80
91 In situ study of the impact of inter- and intra-reader variability on region of interest (ROI) analysis in preclinical molecular imaging. 2013 0.80
92 Assessment of blood flow with (68)Ga-DOTA PET in experimental inflammation: a validation study using (15)O-water. 2014 0.80
93 Dynamic PET with (18)F-Deoxyglucose (FDG) and quantitative assessment with a two-tissue compartment model reflect the activity of glucose transporters and hexokinases in patients with colorectal tumors. 2013 0.80
94 Efficient multicistronic co-expression of hNIS and hTPO in prostate cancer cells for nonthyroidal tumor radioiodine therapy. 2012 0.80
95 (18)F-click labeling of a bombesin antagonist with an alkyne-(18)F-ArBF(3) (-): in vivo PET imaging of tumors expressing the GRP-receptor. 2013 0.80
96 Quantitative differences in [(18)F] NaF PET/CT: TOF versus non-TOF measurements. 2015 0.80
97 Prognostic value of FDG PET/CT-based metabolic tumor volumes in metastatic triple negative breast cancer patients. 2016 0.80
98 Core-based lipid nanoparticles as a nanoplatform for delivery of near-infrared fluorescent imaging agents. 2014 0.79
99 (18)F-FDG imaging of human atherosclerotic carotid plaques reflects gene expression of the key hypoxia marker HIF-1α. 2013 0.79
100 PET/CT in the diagnosis of inflammatory bowel disease in pediatric patients: a review. 2014 0.79
Next 50